Pfizer Bets Big on Cancer Med with $14 Billion Buy of Medivation
Pfizer Bets Big on Cancer Med with $14 Billion Buy of Medivation
Attachment: Pfizer
SUGAR LAND--August 25, 2016--Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas)--Following the industry trend of pipeline and profit growth via acquisition, Pfizer (NYSE:PFE) (New York, New York) is snapping up biotech firm Medivation (NASDAQ:MDVN) (San Francisco) for $14 billion. The very valuable plum on the table is the company's hit prostate cancer drug, Xtandi. Within this article: Details of Pfizer's acquisition efforts.
Subscribe Now!(All Fields Required)
Related Articles
Articles related to this company
- Mexico Registers US$2 Billion in Pharmaceutical Investments
- New England Sees $27 Billion in Projects Under Construction
- Pharma, Manufacturing Lead Indiana to $21.6 Billion of Projects Under Const...
- India Aims to Reduce Dependence on China for Pharma Market
- BMS Investing $400 Million in Dublin Sterile Drug Expansion